Skip to content

Sodium-glucose cotransporter 2 inhibition reduces body weight but not plasma glucose level in patients with type2 diabetes and mild renal failure

Sodium-glucose cotransporter 2 inhibition reduces body weight but not plasma glucose level in patients with type2 diabetes and mild renal failure - Sodium-glucose cotransporter 2 inhibition reduces body weight but not plasma glucose level in patients with type2 diabetes and mild renal failure

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000038103
Enrollment
50
Registered
2019-09-26
Start date
2018-10-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes

Interventions

None listed

Sponsors

Manda Memorial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Outpatients 2) over 20 years old 3) T2DM 4) eGFR over 15 mL/min/1.73 m2 5) Diet and exercise therapies are well performed 6) Patients who are suspected good-compliant 7) Understanding of the study procedures and agreement to participate in the study

Exclusion criteria

Exclusion criteria: 1) Patients suspected of having secondary diabetes (ex. endocrine disease, drug-induced or liver disease) 2) Females who are pregnant or who intend to become pregnant within the study 3) Severe hepatic disease, malignancy, a history of gastrectomy and/or positive for HIV 4) Contraindication with SGLT2 inhibitors 5) Patient who disqualified from the study by the investigator for any reason other than given above.

Design outcomes

Primary

MeasureTime frame
HbA1c and body weight

Secondary

MeasureTime frame
We compared eGFR> 60 with normal kidney function, eGFR <60 as mild renal failure and comparing changes in body weight change with the two groups of HbA1c.

Countries

Japan

Contacts

Public ContactYasuhiro Iijima

Manda Memorial Hospital Diabetes Center

yasuhiro.iijima1203@gmail.com011-231-4032

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026